The working groups in the IQ-DILI Initiative are conducting industry benchmarking and actively engaged in work on white papers on topics related to the management and prevention of DILI. The working groups are focused on:
Abnormal Baselines
Monitoring and assessment of potential DILI in patients with abnormal hepatic biochemical tests at baseline
Causality Assessment
Causality assessment in all patterns of DILI (hepatocellular, cholestatic, hepatic steatosis, vascular) and best practices for drug re-challenge
Immunotherapy
Biomarkers